Safety and efficacy of cadonilimab plus chemotherapy with or without bevacizumab for recurrent or metastatic cervical cancer
10.12354/j.issn.1000-8179.2025.20241462
- VernacularTitle:卡度尼利单抗联合化疗±贝伐珠单抗治疗复发或转移性宫颈癌患者的疗效和安全性
- Author:
Liu CHUNYAN
1
;
Sheng JINDONG
1
;
Liu RUOYAN
1
;
Liu WENXIN
1
Author Information
1. 天津医科大学肿瘤医院妇科肿瘤科,国家恶性肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室,天津市恶性肿瘤临床医学研究中心(天津市 300060)
- Publication Type:Journal Article
- Keywords:
cervical cancer;
immunotherapy;
immune checkpoint inhibitor;
cadonilimab
- From:
Chinese Journal of Clinical Oncology
2025;52(4):172-176
- CountryChina
- Language:Chinese
-
Abstract:
Objective:This study aimed to investigate the safety and efficacy of cadonilimab plus chemotherapy with or without bevacizu-mab in the treatment of recurrent or metastatic cervical cancer(R/M CC).Methods:A retrospective analysis was conducted on 25 patients with R/M CC who were admitted to Tianjin Medical University Cancer Institute&Hospital between August 2022 and June 2024.All patients received cadonilimab plus chemotherapy with or without bevacizumab,followed by cadonilimab as maintenance therapy.Treatment effic-acy and adverse events were comprehensively evaluated,and patients were followed up until October 2024.Results:The median follow-up duration was 18 months(range:4-26 months).The median progression-free survival(PFS)and overall survival were not reached,and the 1-year PFS rate was 77.9%.The objective response rate was 68%,while the disease control rate was 80%.Common adverse reactions in-cluded decreased white blood cell count(40%),nausea(32%),rash(24%),and anemia(24%).No treatment-related deaths occurred during the study period.Conclusions:Cadonilimab plus chemotherapy with or without bevacizumab demonstrated a high objective response rate and a favorable safety profile in patients with R/M CC.However,further studies with larger sample sizes and extended follow-up periods are needed to further validate these findings.
